NCT02184572 · Interventional trial
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Overall registry status Completed
Phase 3
Conditions Measles-Mumps-Rubella Vaccine, Measles; Mumps; Rubella
Delaware Valley sites
- GSK Investigational Site · Sellersville, PA · Bucks County
First posted
Registry updated
Added to the directory